FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945458499> ?p ?o ?g. }

• W2945458499 endingPage "e15052" @default.
• W2945458499 startingPage "e15052" @default.
• W2945458499 abstract "Abstract Rationale: Aromatase inhibitors (AIs) are a class of drugs widely used in the treatment of estrogen sensitive breast and ovarian cancer which convert testosterone to estradiol and androstenedione to estrogen. The AIs of third generation, including anastrazole, letrozole and exemestane, have actually become the standard of care of estrogen-receptor-positive breast cancer in menopausal women and are recommended as adjuvant treatment after surgery in place of/or following tamoxifen. Their main side-effects include reduction in bone mineral density, occurrence of menopausal manifestations and development of musculoskeletal symptoms which are, usually, transient, but sometimes evolve into a typical form of arthritis, such as rheumatoid arthritis (RA). Recently, a pathogenic linkage with other autoimmunity diseases, such as Sjogren syndrome (SjS), anti-synthetase antibody syndrome (ASAS), systemic sclerosis (SS) and subacute cutaneous lupus erythematosus (SCLE), was also described. Patient concerns: Here, we report the first case of a patient with primary antiphospholipid syndrome (APS) developed during treatment with anastrazole. Diagnosis: The patient developed a sudden onset of speech disturbance and disorientation, due to ischemic lesions, after 6 months of AIs therapy and the laboratory examination showed the positivity of anti-Cardiolipin antibodies, anti-β2 Glycoprotein 1 antibodies and Lupus Anticoagulant, so a certain diagnosis of APS was achieved. Interventions: The patient was treated with warfarin associated to hydroxychloroquine and monthly cycles of low doses intravenous immunoglobulins. Outcomes: A good control of the disease was obtained despite the continuation of anastrazole; the patient's clinical and laboratory situation remained not modified after AIs withdrawal. Lessons: We discussed the possible role of anastrazole treatment in inducing APS in our patient, reporting the available literature data about the association between AIs treatment and autoimmune diseases. Furthermore, we analyzed the mechanism of action of estrogens in the pathophysiology of autoimmune rheumatic disorders." @default.
• W2945458499 created "2019-05-29" @default.
• W2945458499 creator A5018403925 @default.
• W2945458499 creator A5028547482 @default.
• W2945458499 creator A5040844392 @default.
• W2945458499 creator A5044887110 @default.
• W2945458499 creator A5079371866 @default.
• W2945458499 date "2019-03-01" @default.
• W2945458499 modified "2023-09-30" @default.
• W2945458499 title "Primary antiphospholipid syndrome during aromatase inhibitors therapy" @default.
• W2945458499 cites W1506209161 @default.
• W2945458499 cites W1529243395 @default.
• W2945458499 cites W165081773 @default.
• W2945458499 cites W1892264977 @default.
• W2945458499 cites W1979636784 @default.
• W2945458499 cites W1982278426 @default.
• W2945458499 cites W1989660169 @default.
• W2945458499 cites W1992856753 @default.
• W2945458499 cites W1999460674 @default.
• W2945458499 cites W2002894389 @default.
• W2945458499 cites W2014200234 @default.
• W2945458499 cites W2015858332 @default.
• W2945458499 cites W2020449909 @default.
• W2945458499 cites W2021390995 @default.
• W2945458499 cites W2025733529 @default.
• W2945458499 cites W2028925036 @default.
• W2945458499 cites W2037976962 @default.
• W2945458499 cites W2051676885 @default.
• W2945458499 cites W2054330426 @default.
• W2945458499 cites W2055972628 @default.
• W2945458499 cites W2056748390 @default.
• W2945458499 cites W2062220664 @default.
• W2945458499 cites W2066304602 @default.
• W2945458499 cites W2072268467 @default.
• W2945458499 cites W2080605094 @default.
• W2945458499 cites W2085927474 @default.
• W2945458499 cites W2090476016 @default.
• W2945458499 cites W2103911945 @default.
• W2945458499 cites W2106286200 @default.
• W2945458499 cites W2112370904 @default.
• W2945458499 cites W2112780046 @default.
• W2945458499 cites W2131578833 @default.
• W2945458499 cites W2131917724 @default.
• W2945458499 cites W2140864886 @default.
• W2945458499 cites W2144133819 @default.
• W2945458499 cites W2151447010 @default.
• W2945458499 cites W2151637765 @default.
• W2945458499 cites W2160197174 @default.
• W2945458499 cites W2161799794 @default.
• W2945458499 cites W2165866678 @default.
• W2945458499 cites W2167385753 @default.
• W2945458499 cites W2167548192 @default.
• W2945458499 cites W2174047760 @default.
• W2945458499 cites W2209149866 @default.
• W2945458499 cites W2343624046 @default.
• W2945458499 cites W2402760855 @default.
• W2945458499 cites W2408071762 @default.
• W2945458499 cites W2410565636 @default.
• W2945458499 cites W2531590834 @default.
• W2945458499 cites W28052452 @default.
• W2945458499 cites W2806951932 @default.
• W2945458499 cites W2977055562 @default.
• W2945458499 cites W2987949485 @default.
• W2945458499 cites W55130308 @default.
• W2945458499 cites W91616619 @default.
• W2945458499 cites W165617374 @default.
• W2945458499 cites W2138652581 @default.
• W2945458499 doi "https://doi.org/10.1097/md.0000000000015052" @default.
• W2945458499 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6455664" @default.
• W2945458499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30921233" @default.
• W2945458499 hasPublicationYear "2019" @default.
• W2945458499 type Work @default.
• W2945458499 sameAs 2945458499 @default.
• W2945458499 citedByCount "18" @default.
• W2945458499 countsByYear W29454584992019 @default.
• W2945458499 countsByYear W29454584992020 @default.
• W2945458499 countsByYear W29454584992021 @default.
• W2945458499 countsByYear W29454584992022 @default.
• W2945458499 countsByYear W29454584992023 @default.
• W2945458499 crossrefType "journal-article" @default.
• W2945458499 hasAuthorship W2945458499A5018403925 @default.
• W2945458499 hasAuthorship W2945458499A5028547482 @default.
• W2945458499 hasAuthorship W2945458499A5040844392 @default.
• W2945458499 hasAuthorship W2945458499A5044887110 @default.
• W2945458499 hasAuthorship W2945458499A5079371866 @default.
• W2945458499 hasBestOaLocation W29454584991 @default.
• W2945458499 hasConcept C121608353 @default.
• W2945458499 hasConcept C126322002 @default.
• W2945458499 hasConcept C2775860665 @default.
• W2945458499 hasConcept C2776166826 @default.
• W2945458499 hasConcept C2776874634 @default.
• W2945458499 hasConcept C2776912625 @default.
• W2945458499 hasConcept C2777575956 @default.
• W2945458499 hasConcept C2778812593 @default.
• W2945458499 hasConcept C2779123688 @default.
• W2945458499 hasConcept C2779134260 @default.
• W2945458499 hasConcept C2780868729 @default.
• W2945458499 hasConcept C3008058167 @default.

• next